Jaguar Health, Inc. (JAGX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

Market Cap

$3.08M

MomentumView details →

1D Return

−14.06%

YTD Return

−98.16%

RSI (14)

24.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

Market Cap

$3.08M

RSI (14)

24.2

MomentumView details →

1D Return

−14.06%

YTD Return

−98.16%

SummaryUpdated Jun 1, 2026

Jaguar Health, Inc. (NASDAQ:JAGX) is a commercial-stage pharmaceutical company founded in 2013 and headquartered in San Francisco, California. The company went public in May 2015 and focuses on developing prescription medicines for gastrointestinal distress, particularly chronic and debilitating diarrhea conditions in both humans and animals. Jaguar Health operates through two primary segments: Human Health and Animal Health, with its lead commercial product being <b>Mytesi</b>, an FDA-approved treatment for HIV-related diarrhea.

Ask drillr about Jaguar Health, Inc. →

ProfitabilityView details →

Gross Margin

82.31%

Net Margin

−131.76%

EBITDA Margin

−144.11%

ROE (TTM)

−554.01%

ROA (TTM)

−107.18%

Asset Turnover

0.78x

GrowthView details →

Revenue YoY

+135.52%

EPS YoY

+82.99%

FCF YoY

+75.55%

Revenue CAGR 3Y

−1.26%

EPS CAGR 3Y

+82.42%

EBITDA YoY

+5.62%

EarningsView details →

EPS (Actual)

−$15.70

EPS Surprise

69.89%

Beats (12Q)

5/12

Next Q EPS Est

−$40.95

Avg Surprise (4Q)

8.80%

Rev Surprise

−71.11%

Capital & dividendView details →

Debt/Equity

2.52x

Current Ratio

0.69x

Quick Ratio

0.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

27.82M

Net Income (TTM)

−36.65M

Op. CF (TTM)

−6.74M

Next earningsNov 12, 2026 →

Latest newsMore news →

Jaguar Health initiated the commercial launch of Neonorm Dog, a non-prescription plant-based product for dogs, and plans to make it available through Amazon and Chewy soon.10d ago

Jaguar Health reported Q2 2026 revenue of $1.225 million, down 59% year-over-year, with a net loss of $12.69 million and diluted EPS of -$15.68.17d ago

Similar companies

SciSparc Ltd.SPRC Aptevo Therapeutics Inc.APVO 60 Degrees Pharmaceuticals, Inc.SXTP Artelo Biosciences, Inc.ARTL Affimed N.V.AFMD Curis, Inc.CRIS Find similar companies →

Latest newsMore news →

Jaguar Health initiated the commercial launch of Neonorm Dog, a non-prescription plant-based product for dogs, and plans to make it available through Amazon and Chewy soon.10d ago Jaguar Health reported Q2 2026 revenue of $1.225 million, down 59% year-over-year, with a net loss of $12.69 million and diluted EPS of -$15.68.17d ago Jaguar Health satisfied the conditions to receive a $2 million holdback payment from Future Pak under its U.S. commercial licensing agreement for Mytesi and Canalevia-CA1.31d ago